ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
3D Bioprinted Blood-Brain-Tumor Barrier Spheroid-Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS-Producing Ruthenium as a Potential Therapeutic Candidate.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The blood-brain-tumor barrier (BBTB) penetration by anticancer drugs and their effects on glioblastoma (GBM) are assessed using 3D bioprinted-spheroids. Comparative analysis reveals prominent cytoplasmic mixing between pericytes and the human GBM cell line U-87MG, expressions of tight junction proteins ZO-1, occludin, and claudin-5, which act as a barrier to the paracellular transport across BBTB, and the expression of ABC transporter such as P-glycoprotein (P-gp) in the vascular endothelial cell layer of BBTB spheroids. Anticancer drug-induced U-87 MG cell death is quantified through in situ imaging of spheroids using a cancer cell death probe. Paclitaxel and cisplatin, known P-gp substrates, do not demonstrate transcellular transport in BBTB spheroids, whereas temozolomide and a ruthenium (Ru) compound induce marked U-87 MG cell death. Relative BBTB permeability is calculated as a function of IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.